← All Sponsors
SPONSOR

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Schizophrenia
NCT05304767 Phase 3
Recruiting

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
United States, Bulgaria, Czechia View Trial →